Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Good
|
New words:
abuse, AgreementSM, Alliance, assay, attention, BARDA, begun, Biomedical, box, Buerger, burn, Category, cGCP, cGMP, chairmen, Chart, Chen, clawback, clonogenic, cohort, compliant, countermeasure, deep, departure, derecognized, DoD, domain, donor, earlier, earliest, erosion, false, fourteen, fourteenth, graft, GvHD, HIPAA, histopathological, husband, implicated, inappropriate, inInternal, Isaac, Mark, maximum, NASA, negotiate, northern, PAD, Portability, profile, prophylactic, provisional, PwC, recast, regime, regimen, regular, relieve, retroactive, ROU, Rutherford, Save, serum, Shai, Shalav, shifting, shortly, Sigma, southern, split, Switching, tailored, Takeda, transformative, volume
Removed:
abovementioned, ADI, amending, broader, calling, cancelled, classify, classifying, complied, construction, contractor, copy, cybersecurity, decide, deducted, deliverable, deploy, determinable, disrupt, dissemination, domestic, electronic, enactment, evaluated, expose, financed, forfeitable, higher, hotel, Hypertension, incident, injected, instrument, larger, letter, merger, misappropriation, mitigate, NE, noticed, occurrence, PAH, physical, premium, principle, Privileged, progressive, publicity, pulmonary, qualification, read, regained, reputational, robust, Rock, Room, round, selling, separate, straight, Street, strength, territory, unit, vacation, waiving, Washington
Filing tables
Filing exhibits
- 10-K Annual report
- 3.1 Composite Articles of Incorporation
- 3.2 Composite Marked Articles of Incorporation
- 4.3 Description of Securities
- 10.8 Summary of Directors Ongoing Compensation
- 10.18 Stock Option Agreement
- 10.19 Restricted Stock Agreement
- 10.20 Restricted Stock Agreement for Israelis
- 23.1 Consent of Kost Forer Gabbay & Kasierer, a Member of Ernst & Young Global
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
- Download Excel data file
- View Excel data file
PLUR similar filings
Filing view
External links
Exhibit 10.8
Summary of Directors Ongoing Compensation
As of June 30, 2019 our non-executive officer directors receive cash compensation as follows:
● | Annual compensation of $15,000; |
● | Meeting participation fee of $935 per in-person meeting; and |
● | For meeting participation by telephone, $435 per meeting. |
If the compensation is paid in New Israeli Shekels (“NIS”), the exchange rate of the directors’ fees used to calculate the fees will be not less then $4.25 per NIS.
The directors are also entitled to two and a half percent (2.5%) from amounts received by us from non diluting funding and strategic deals, as determined by the Board of Directors and/or the Compensation Committee.